Ear Nose Throat J:持久过敏性鼻炎患者中氧化应激和硫醇/二硫化物平衡评估

2020-08-13 AlexYang MedSci原创

最近,有研究人员评估了药物治疗对硫醇/二硫化物平衡的影响,尽管过敏性刺激持续存在。

最近,有研究人员评估了药物治疗对硫醇/二硫化物平衡的影响,尽管过敏性刺激持续存在。

研究是一个前瞻性的观察研究,包括了35名持久过敏性鼻炎(AR)患者。研究人员对所有患者进行了皮刺测试,并使用Sino-nasal Outcome Test-22(SNOT-22)测试评估了鼻窦症状。研究人员使用了一种新型自动分光光度法测定硫醇/二硫化物稳态平衡参数,并进行统计学比较,并在治疗的第二个月测量了血清总硫醇(TT)、天然硫醇(SH)、二硫醇(SS)、二硫醇/天然硫醇(SS/SH)、二硫醇/总硫醇(SS/TT)、天然硫醇/总硫醇(SH/TT)比值。

治疗前后血清硫醇值

参与研究的35名患者中,20名(58%)为女性。患者的平均年龄为33.17±9.9岁。治疗后,二硫化物、SS/SH和SS/TT比例显著下降(P<0.5),而SH和SH/TT的比例显著增加(P<0.05)。在第二个月SH测量均值显著增加(P=0.001),但TT测量均值在治疗后无明显变化(P=0.058)。SS测量值在治疗第二个月显著减少(P=0.003)。

SNOT-22差异与二硫化物关系

最后,研究人员指出,硫醇/二硫化物平衡可以作为持久AR治疗效果的标记。尽管处在过敏原接触中,治疗后SH水平的增加表明了氧化应激的减弱。

原始出处:

Ayse E Göker, Maide H Alagöz, Tolgar L Kumral et al. An Evaluation of Oxidative Stress With Thiol/Disulfide Homeostasis in Patients With Persistent Allergic Rhinitis. Ear Nose Throat J. Jul 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1661555, encodeId=c758166155574, content=<a href='/topic/show?id=aea3131932d' target=_blank style='color:#2F92EE;'>#OAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13193, encryptionId=aea3131932d, topicName=OAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37ad25322582, createdName=12498561m40(暂无昵称), createdTime=Fri Feb 05 11:35:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047293, encodeId=b9bf204e2935d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 22 13:35:05 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811446, encodeId=3789811446e6, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0e2496925, createdName=1248e28am39暂无昵称, createdTime=Thu Aug 20 16:46:22 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445327, encodeId=c656144532eef, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sat Aug 15 05:35:05 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808511, encodeId=baef8085112d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 13 19:12:38 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1661555, encodeId=c758166155574, content=<a href='/topic/show?id=aea3131932d' target=_blank style='color:#2F92EE;'>#OAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13193, encryptionId=aea3131932d, topicName=OAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37ad25322582, createdName=12498561m40(暂无昵称), createdTime=Fri Feb 05 11:35:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047293, encodeId=b9bf204e2935d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 22 13:35:05 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811446, encodeId=3789811446e6, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0e2496925, createdName=1248e28am39暂无昵称, createdTime=Thu Aug 20 16:46:22 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445327, encodeId=c656144532eef, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sat Aug 15 05:35:05 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808511, encodeId=baef8085112d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 13 19:12:38 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1661555, encodeId=c758166155574, content=<a href='/topic/show?id=aea3131932d' target=_blank style='color:#2F92EE;'>#OAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13193, encryptionId=aea3131932d, topicName=OAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37ad25322582, createdName=12498561m40(暂无昵称), createdTime=Fri Feb 05 11:35:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047293, encodeId=b9bf204e2935d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 22 13:35:05 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811446, encodeId=3789811446e6, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0e2496925, createdName=1248e28am39暂无昵称, createdTime=Thu Aug 20 16:46:22 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445327, encodeId=c656144532eef, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sat Aug 15 05:35:05 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808511, encodeId=baef8085112d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 13 19:12:38 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1661555, encodeId=c758166155574, content=<a href='/topic/show?id=aea3131932d' target=_blank style='color:#2F92EE;'>#OAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13193, encryptionId=aea3131932d, topicName=OAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37ad25322582, createdName=12498561m40(暂无昵称), createdTime=Fri Feb 05 11:35:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047293, encodeId=b9bf204e2935d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 22 13:35:05 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811446, encodeId=3789811446e6, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0e2496925, createdName=1248e28am39暂无昵称, createdTime=Thu Aug 20 16:46:22 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445327, encodeId=c656144532eef, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sat Aug 15 05:35:05 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808511, encodeId=baef8085112d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 13 19:12:38 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1661555, encodeId=c758166155574, content=<a href='/topic/show?id=aea3131932d' target=_blank style='color:#2F92EE;'>#OAT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13193, encryptionId=aea3131932d, topicName=OAT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37ad25322582, createdName=12498561m40(暂无昵称), createdTime=Fri Feb 05 11:35:05 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047293, encodeId=b9bf204e2935d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Feb 22 13:35:05 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811446, encodeId=3789811446e6, content=。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0e2496925, createdName=1248e28am39暂无昵称, createdTime=Thu Aug 20 16:46:22 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445327, encodeId=c656144532eef, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Sat Aug 15 05:35:05 CST 2020, time=2020-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808511, encodeId=baef8085112d, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 13 19:12:38 CST 2020, time=2020-08-13, status=1, ipAttribution=)]
    2020-08-13 ms3000000449926787

    学习

    0

相关资讯

Cell Death Dis:ACER3通过降低细胞氧化应激反应缓解非酒精性脂肪肝炎

棕榈酸过量与非酒精性脂肪肝炎(NASH)中神经酰胺的代谢异常密切相关。神经酰胺是一种重要的生物活性脂质,介导NASH中的棕榈酸脂毒性。但神经酰胺酶在NASH中催化神经酰胺水解的作用机制目前尚不清楚。

Pharm Biol:苋菜和菜籽油对肥胖患者中性粒细胞氧化代谢的影响

苋菜油和低芥酸菜籽油经常使用。由于苋菜具有突出的营养价值,因此备受关注。苋菜油是高度不饱和脂肪的丰富来源,因此对于肥胖者而言,它可能是一种有价值的饮食替代品。假定活性氧(ROS)参与全身性炎症和氧化应

Cell Death Dis:PGC-1α低表达加剧肝细胞上皮-间质转化及肝纤维化

肝纤维化发生于包括肝炎及慢性酒精中毒在内的多种肝病中,可导致瘢痕形成,造成肝损伤。肝纤维化是一种伤口愈合反应,其特征是细胞外基质(ECM)中蛋白沉积过多、肝细胞损伤、肝小叶畸变及血管结构改变。如果不加

NAT IMMUNOL:神经炎症中氧化应激的转录谱分析和治疗靶点研究

最近,研究人员提供了神经炎症性疾病中的氧化应激先天免疫细胞图谱,并报告了新的可成药途径的发现。

Cell Death Dis:抑制甲状腺激素信号通路或可用于治疗老年性黄斑变性

老年性黄斑变性(AMD)是老年人失明的主要原因。干性AMD的主要特征表现为视网膜色素上皮(RPE)和感光细胞逐渐发生黄斑变性,且该疾病的核心问题为RPE细胞的氧化性损伤或营养不良。最近基于正常人群及患者的研究表明,高游离血清甲状腺激素(TH)水平与AMD风险升高息息相关。该研究发现,在氧化应激诱导AMD的小鼠模型中,抑制TH信号能够引起RPE细胞及感光细胞的损伤/细胞死亡。通过抗甲状腺药物治疗及碘

Biol Trace Elem Res:多囊卵巢综合征患者的氧化应激水平高于正常者

本研究评估了PCOS患者的血清铜和镁以及总抗氧化能力水平。在这方面,研究了铜和镁与总抗氧化能力(TAC)的可能关联。